CoChat

Prognostic significance of CT-determined sarcopenia in older patients with advanced squamous cell lung cancer treated with programmed death-1 inhibitors

Ying, Lin, Xu, Liqian, Yang, Ji, Zhang, Qin · 2024 · Scientific Reports
Cited by 15

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Sarcopenia has been associated with higher toxicity induced by anti-cancer treatments and shorter survival in patients with squamous cell lung carcinoma (SqCLC). Over the past few decades, immune checkpoint inhibitors (ICIs) significantly improves the prognosis. However, few clinical studies explored the effectiveness of immunotherapy in the elderly population. Here, we performed a retrospective analysis to determine the prognostic role of sarcopenia in older patients with SqCLC receiving ICIs. We retrospectively assessed SqCLC patients who were treated with PD-1 inhibitors and all patients were at least 70 years old. Pre-treatment sarcopenic status was determined by analyzing L3 skeletal muscle index (SMI) with chest CT. Progression-free survival (PFS), disease-specific survival (DSS) and overall survival (OS) were estimated using the Kaplan–Meier method, and the differences in survival were compared using the log-rank test. Among 130 male SqCLC patients, 93 had sarcopenia. Patients with sarcopenia were older and had a lower body mass index (BMI). Over an average follow-up of 20.8 months, 92 patients died. For all 130 patients, the mean OS was 13.3 months. Patients with sarcopenia had a significantly shorter OS and PFS than those without sarcopenia (OS, 12.4 ± 5.2 months vs. 15.5 ± 10.5 months, P = 0.028; PFS, 6.4 ± 2.9 months vs. 7.7 ± 4.2 months; P = 0.035). Multivariable analysis showed that sarcopenia was an independent prognostic factor for shorter OS and PFS. CT-determined sarcopenia is an independent prognostic factor for older patients with SqCLC receiving ICIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-024-62825-2

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 28

  1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021). · DOI · Paper page
  2. Zhang, S. et al. Cancer incidence and mortality in China, 2015. J. Natl. Cancer Cent. 1(1), 2–11 (2021). · DOI · Paper page
  3. Cheng, T. Y. et al. The international epidemiology of lung cancer: Latest trends, disparities, and tumor characteristics. J. Thorac. Oncol. 11(10), 1653–1671 (2016). · DOI · Paper page
  4. Jemal, A. et al. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J. Natl. Cancer Inst. https://doi.org/10.1093/jnci/djx030 (2017). · DOI · Paper page
  5. Hirsch, F. R. et al. Lung cancer: Current therapies and new targeted treatments. Lancet 389(10066), 299–311 (2017). · DOI · Paper page
  6. Rami-Porta, R. et al. Lung cancer staging: A concise update. Eur. Respir. J. 51(5), 1800190 (2018). · DOI · Paper page
  7. Friedlaender, A. et al. Next generation sequencing and genetic alterations in squamous cell lung carcinoma: Where are we today?. Front. Oncol. 9, 166 (2019). · DOI
  8. Langer, C. J. et al. Incremental innovation and progress in advanced squamous cell lung cancer: Current status and future impact of treatment. J. Thorac. Oncol. 11(12), 2066–2081 (2016). · DOI
  9. Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379(21), 2040–2051 (2018). · DOI · Paper page
  10. Cruz-Jentoft, A. J. & Sayer, A. A. Sarcopenia. Lancet 393(10191), 2636–2646 (2019). · DOI · Paper page
  11. Bozzetti, F. Forcing the vicious circle: Sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Ann. Oncol. 28(9), 2107–2118 (2017). · DOI · Paper page
  12. Pring, E. T. et al. Cancer cachexia and myopenia-update on management strategies and the direction of future research for optimizing body composition in cancer—A narrative review. Cancer Treat. Rev. 70, 245–254 (2018). · DOI
  13. Yang, M. et al. Prognostic value of sarcopenia in lung cancer: A systematic review and meta-analysis. Chest 156(1), 101–111 (2019). · DOI · Paper page
  14. Shoji, F. et al. Relationship between preoperative sarcopenia status and immuno-nutritional parameters in patients with early-stage non-small cell lung cancer. Anticancer Res. 37(12), 6997–7003 (2017).
  15. Roch, B. et al. Cachexia-sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer 143, 19–26 (2020). · DOI
  16. Lyman, G. H., Lyman, C. H. & Agboola, O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10(6), 427–437 (2005). · DOI · Paper page
  17. DeSantis, C. E. et al. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J. Clin. 69(6), 452–467 (2019). · DOI · Paper page
  18. Prado, C. M. et al. Prevalence and clinical implications of sarcopenic obesityobesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol. 9(7), 629–635 (2008). · DOI · Paper page
  19. Charlson, M. E. et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 40(5), 373–383 (1987). · DOI · Paper page
  20. Zhao, L. et al. Association between Charlson comorbidity index score and outcome in patients with stage IIIB–IV non-small cell lung cancer. BMC Pulm. Med. 17(1), 112 (2017). · DOI
  21. Daly, L. E. et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br. J. Cancer 116(3), 310–317 (2017). · DOI · Paper page
  22. Shiroyama, T. et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. Sci. Rep. 9(1), 2447 (2019). · DOI · Paper page
  23. Bilen, M. A. et al. combined effect of sarcopenia and systemic inflammation on survival in patients with advanced stage cancer treated with immunotherapy. Oncologist 25(3), e528–e535 (2020). · DOI
  24. Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15(8), 486–499 (2015). · DOI · Paper page
  25. Tsang, N. M. et al. Overweight and obesity predict better overall survival rates in cancer patients with distant metastases. Cancer Med. 5(4), 665–675 (2016). · DOI
  26. Schlesinger, S. et al. Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: A prospective study and meta-analysis. Cancer Causes Control 25(10), 1407–1418 (2014). · DOI
  27. Berger, N. A. Obesity and cancer pathogenesis. Ann. NY. Acad. Sci. 1311, 57–76 (2014). · DOI · Paper page
  28. Fusco, D. et al. Comprehensive geriatric assessment in older adults with cancer: Recommendations by the Italian society of geriatrics and gerontology (SIGG). Eur. J. Clin. Invest. 51(1), e13347 (2021). · DOI

Cited by

See all 15

Metadata

Authors
Ying, L., Xu, L., Yang, J., & Zhang, Q.
Venue
Scientific Reports
Published
2024-05-26
Volume
14
Issue
1
ISSN
2045-2322
Cited by
15
References
5
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.